Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease

Por Rob, Daniel, Marek, Josef, Dostálová, Gabriela, Goláň, Lubor, Linhart, Aleš
Publicado no PLoS One (2016)

Correction: Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease

Por Rob, Daniel, Marek, Josef, Dostálová, Gabriela, Goláň, Lubor, Linhart, Aleš
Publicado no PLoS One (2017)

Replacement of α-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients

Por Keslová-Veselíková, Jana, Hůlková, Helena, Dobrovolný, Robert, Asfaw, Befekadu, Poupětová, Helena, Berná, Linda, Sikora, Jakub, Goláň, Lubor, Ledvinová, Jana, Elleder, Milan
Publicado em 2008

The coincidence of IgA nephropathy and Fabry disease

Por Maixnerová Dita, Tesař Vladimír, Ryšavá Romana, Reiterová Jana, Poupětová Helena, Dvořáková Lenka, Goláň Lubor, Neprašová Michaela, Kidorová Jana, Merta Miroslav, Honsová Eva
Publicado em 2013-01-01

The coincidence of IgA nephropathy and Fabry disease

Por Maixnerová, Dita, Tesař, Vladimír, Ryšavá, Romana, Reiterová, Jana, Poupětová, Helena, Dvořáková, Lenka, Goláň, Lubor, Neprašová, Michaela, Kidorová, Jana, Merta, Miroslav, Honsová, Eva
Publicado em 2013

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Por Goláň, Lubor, Goker-Alpan, Ozlem, Holida, Myrl, Kantola, Ikka, Klopotowski, Mariusz, Kuusisto, Johanna, Linhart, Aleš, Musial, Jacek, Nicholls, Kathleen, Gonzalez-Rodriguez, Derlis, Sharma, Reena, Vujkovac, Bojan, Chang, Peter, Wijatyk, Anna
Publicado no Drug Des Devel Ther (2015)